Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of APG333 in healthy volunteers

Next Previous
Trial Profile

A clinical study of APG333 in healthy volunteers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 333 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man

Most Recent Events

  • 10 Dec 2024 According to Apogee Therapeutics media release, company announced that it has initiated dosing of healthy volunteers in this trial. and company expects interim data from the trial in the second half of 2025.
  • 02 Dec 2024 According to Apogee Therapeutics media release, data expected in the second half of 2025.
  • 18 Nov 2024 According to Apogee Therapeutics media release, company plans to initiate Phase 1 clinical trial in healthy volunteers of APG333 in late 2024 or early 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top